XR 5000

Drug Profile

XR 5000

Alternative Names: AC; Acridine carboxamide; DACA; NSC 601316; SN 22995

Latest Information Update: 26 Feb 2001

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Auckland Cancer Society Research Centre
  • Developer Cancer Research UK; Xenova Group
  • Class Antineoplastics
  • Mechanism of Action DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Glioblastoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 26 Feb 2001 Discontinued-II for Glioblastoma in Europe (Infusion)
  • 26 Feb 2001 Discontinued-II for Non-small cell lung cancer in Europe (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top